Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
We are also applying autoantibody profiling to patient stratification in immuno-oncology, where we measure how the immune system is recognising the presence of tumour antigens.
Dr Michael FisherCommercial Director
OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.
The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.